Antivirals for treatment of HCV infections

DrugDrug NameDrug Indication
DB00503RitonavirIndicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
DB00811RibavirinIndicated for the treatment of chronic Hepatitis C virus (HCV) infection in combination with other antiviral agents with the intent to cure or achieve a sustained virologic response (SVR). Typically added to improve SVR and reduce relapse rates [A19644]. The addition of ribavirin in Technivie therapy indicated for treating HCV genotype 1a and 4 infections is recommended in patients with or without cirrhosis. Resistance: viral genetic determinants resulting in variable response to ribavirin therapy has not been yet determined.
DB05521TelaprevirTelaprevir, when used in combination with [DB00811], [DB00008], and [DB00022] is indicated for use in the treatment of chronic HCV genotype 1 infection in adults [FDA Label].
DB06290SimeprevirIndicated for the treatment of adults with chronic hepatitis C virus (HCV) infection: typically in combination with sofosbuvir in patients with HCV genotype 1 without cirrhosis or with compensated cirrhosis and in combination with peginterferon alfa (Peg-IFN-alfa) and ribavirin (RBV) in patients with HCV genotype 1 or 4 without cirrhosis or with compensated cirrhosis. Resistance: Reduced susceptibility to simeprevir was most commonly associated with the viral NS3 Q80K polymorphism. Amino acid substitutions at NS3 positions S122, R155 and/or D168 are also shown to reduce susceptibility to simeprevir in genotype 1a/b patients.
DB08873BoceprevirBoceprevir, when used in combination with [DB00811], [DB00008], and [DB00022] is indicated for use in the treatment of chronic HCV genotype 1 infection in adults [FDA Label].
DB08934SofosbuvirSofosbuvir is used in combination therapy with other antiviral medications to treat chronic hepatitis C virus (HCV) infected patients with HCV genoptypes 1-6, and to treat HCV and HIV co-infected patients. Depending on the level of cirrhosis or decompensation, combination therapy can also include either ribavirin alone or ribavirin and peg-interferon alfa. When used in combination with [DB09027] as the combination product Harvoni, sofosbuvir has the following indications: treatment of genotypes 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis; in combination with [DB00811] for genotype 1 infection with decompensated cirrhosis; or in combination with [DB00811] for the treatment of genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis. When used in combination with [DB11613] as the combination product Epclusa, sofosbuvir is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotypes 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, or in combination with [DB00811] if associated with decompensated cirrhosis. Resistance: Reduced susceptibility to sofosbuvir has been associated with the NS5B substitution mutation S282T [A19634].
DB09027LedipasvirWhen used in combination with the antiviral medication [DB08934] as the commercially available product Harvoni, ledipasvir is indicated for the treatment of HCV genotypes 1, 4, 5, and 6 with or without [DB00811] depending on the level of liver damage or cirrhosis [FDA Label]. Its use has also proven successful in the treatment of HCV in patients co-infected with HIV [A19627].
DB09102DaclatasvirIndicated for use with sofosbuvir, with or without ribavirin, for the treatment of chronic HCV genotype 1a/b or 3 infection. The dosing regimen of 60mg daclatasvir 60 mg with 400mg sofosbuvir once a day is recommended for both genontypes. Resistance: Reduced susceptibility to daclatasvir was associated with the polymorphisms at NS5A amino acid positions M28, Q30, L31, and Y93 in genotypes 1a, 1b, and 3a patients. NS5A Resistance Testing is recommended for HCV genotype 1a-infected patients with cirrhosis prior to the initiaition of the treatment, as the risk of resistance development is higher in genotype 1a patients.
DB09183DasabuvirDasabuvir, in combination with [DB09296], [DB09297], and [DB00503] (as Viekira Pak) is indicated for the treatment of patients with HCV genotype 1a with [DB00811] or genotype 1b without [DB00811] including those with compensated cirrhosis [FDA Label].
DB09296OmbitasvirWhen used in combination with [DB09297] and [DB00503] (as the fixed dose product Technivie), Ombitasvir is indicated in combination with [DB00811] for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis [L866]. When used in combination with [DB09297], [DB00503], and [DB09183] (as the fixed dose product Viekira Pak), Ombitasvir is indicated for the treatment of HCV genotype 1b and ,when combined with [DB00811], for the treatment of HCV genotype 1a [FDA Label]
DB09297ParitaprevirWhen used within the fixed-dose combination product with [DB09296], [DB09183], and [DB00503] as the FDA-approved product Viekira Pak, paritaprevir is indicated for the treatment of HCV genotype 1b without cirrhosis or with compensated cirrhosis, and when combined with [DB00811] for the treatment of HCV genotype 1a without cirrhosis or with compensated cirrhosis. When used within the fixed-dose combination product with [DB09296] and [DB00503] as the FDA- and Health Canada-approved product Technivie, paritaprevir is indicated in combination with [DB00811] for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis. When used within the fixed-dose combination product with [DB09296], [DB09183], and [DB00503] as the Health Canada-approved, commercially available product Holkira Pak, paritaprevir is indicated for the treatment of HCV genotype 1b with or without cirrhosis, and when combined with [DB00811] for the treatment of HCV genotype 1a with or without cirrhosis.
DB11574ElbasvirElbasvir, when used in combination with [DB11575] as the combination product Zepatier, is indicated for use with or without ribavirin for the treatment of chronic HCV genotypes 1 or 4 infection in adults [FDA Label].
DB11575GrazoprevirGrazoprevir is indicated in combination with [DB11574] (as the fixed dose combination product Zepatier) with or without [DB00811] for treatment of chronic HCV genotypes 1a, 1b, or 4 infection in adults.
DB11586AsunaprevirAsunaprevir is indicated in combination with other agents for the treatment of chronic hepatitis C in adult patients with hepatitis C virus genotypes 1 or 4 and compensated liver cirrhosis.[L2278] Hepatitis C is a liver disease caused by the hepatitis C virus. The chronic state of this condition accounts for 60-80% of the cases from which the risk of cirrhosis of the liver within 20 years is of around 15-30%.[L2281] The genotype 1 is the most common type of hepatitis C in the United States and the most difficult to treat.[L2282]
DB11613VelpatasvirVelpatasvir is used in combination therapy with other antiviral medications to treat chronic hepatitis C virus (HCV) infected patients with HCV genoptypes 1-6, and to treat HCV and HIV co-infected patients. Depending on the level of cirrhosis or decompensation, combination therapy can also include therapy with [DB00811]. When used in combination with [DB08934] as the combination product Epclusa, Velpatasvir is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis, or in combination with [DB00811] if associated with decompensated cirrhosis [FDA Label].
DB11808FaldaprevirNot Available
DB12026VoxilaprevirVosevi (Voxilaprevir/[DB08934]/[DB11613]) is approved for use in patients with genotypes 1-6 who have been previously treated with an NS5A inhibitor, or patients with genotypes 1a or 3 infection who have previously been treated with an HCV regimen containing [DB08934] without an NS5A inhibitor [L935].
DB13878PibrentasvirIndicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is also indicated for the treatment of adult patients with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both [FDA Label].
DB13879GlecaprevirIndicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is also indicated for the treatment of adult patients with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both [FDA Label].
DrugDrug NameTargetType
DB00503RitonavirHuman immunodeficiency virus type 1 proteasetarget
DB00503RitonavirCytochrome P450 2D6enzyme
DB00503RitonavirCytochrome P450 2C9enzyme
DB00503RitonavirCytochrome P450 2C19enzyme
DB00503RitonavirCytochrome P450 2B6enzyme
DB00503RitonavirCytochrome P450 2C8enzyme
DB00503RitonavirMultidrug resistance protein 1transporter
DB00503RitonavirMultidrug resistance-associated protein 1transporter
DB00503RitonavirCanalicular multispecific organic anion transporter 1transporter
DB00503RitonavirSolute carrier organic anion transporter family member 1A2transporter
DB00503RitonavirATP-binding cassette sub-family G member 2transporter
DB00503RitonavirSolute carrier organic anion transporter family member 1B1transporter
DB00503RitonavirCytochrome P450 1A2enzyme
DB00503RitonavirCytochrome P450 2E1enzyme
DB00503RitonavirNuclear receptor subfamily 1 group I member 2target
DB00503RitonavirSerum albumincarrier
DB00503RitonavirCytochrome P450 3A4enzyme
DB00503RitonavirCytochrome P450 3A5enzyme
DB00503RitonavirCytochrome P450 3A7enzyme
DB00503RitonavirCytochrome P450 3A43enzyme
DB00503RitonavirUDP-glucuronosyltransferase 1-1enzyme
DB00503RitonavirSolute carrier organic anion transporter family member 2B1transporter
DB00503RitonavirBile salt export pumptransporter
DB00811RibavirinRNA-directed RNA polymerase Ltarget
DB00811RibavirinEctonucleotide pyrophosphatase/phosphodiesterase family member 1target
DB00811RibavirinRNA-directed RNA polymerase catalytic subunittarget
DB00811RibavirinCytosolic purine 5'-nucleotidasetarget
DB00811RibavirinInosine-5'-monophosphate dehydrogenase 1target
DB00811RibavirinGenome polyproteintarget
DB00811RibavirinInosine-5'-monophosphate dehydrogenase 2target
DB00811RibavirinAdenosine kinaseenzyme
DB00811RibavirinEquilibrative nucleoside transporter 1transporter
DB00811RibavirinSolute carrier family 28 member 3transporter
DB05521TelaprevirCytochrome P450 3A4enzyme
DB05521TelaprevirNS3/4A proteintarget
DB05521TelaprevirMultidrug resistance protein 1transporter
DB05521TelaprevirSerum albumincarrier
DB05521TelaprevirAlpha-1-acid glycoprotein 1carrier
DB05521TelaprevirSolute carrier organic anion transporter family member 1B1target
DB05521TelaprevirSolute carrier organic anion transporter family member 2B1target
DB05521TelaprevirCytochrome P450 3A5enzyme
DB06290SimeprevirNS3 proteasetarget
DB06290SimeprevirSerum albumincarrier
DB06290SimeprevirCytochrome P450 1A2enzyme
DB06290SimeprevirMultidrug resistance protein 1transporter
DB06290SimeprevirSolute carrier organic anion transporter family member 1B1transporter
DB06290SimeprevirSolute carrier organic anion transporter family member 1B3transporter
DB06290SimeprevirCytochrome P450 3A4enzyme
DB06290SimeprevirCanalicular multispecific organic anion transporter 1transporter
DB06290SimeprevirATP-binding cassette sub-family G member 2transporter
DB06290SimeprevirSolute carrier organic anion transporter family member 2B1transporter
DB06290SimeprevirSodium/bile acid cotransportertransporter
DB06290SimeprevirBile salt export pumptransporter
DB08873BoceprevirCytochrome P450 3A4enzyme
DB08873BoceprevirCytochrome P450 3A5enzyme
DB08873BoceprevirMultidrug resistance protein 1transporter
DB08873BoceprevirNS3/4A proteintarget
DB08934SofosbuvirMultidrug resistance protein 1transporter
DB08934SofosbuvirATP-binding cassette sub-family G member 2transporter
DB08934SofosbuvirRNA-dependent RNA-polymerasetarget
DB08934SofosbuvirLysosomal protective proteinenzyme
DB08934SofosbuvirCarboxylesteraseenzyme
DB08934SofosbuvirHistidine triad nucleotide-binding protein 1enzyme
DB08934SofosbuvirUMP-CMP kinaseenzyme
DB08934SofosbuvirNucleoside diphosphate kinase Aenzyme
DB09027LedipasvirNonstructural protein 5Atarget
DB09027LedipasvirMultidrug resistance protein 1transporter
DB09027LedipasvirATP-binding cassette sub-family G member 2transporter
DB09102DaclatasvirNonstructural Protein 5A (NS5A)target
DB09102DaclatasvirCytochrome P450 3A5enzyme
DB09102DaclatasvirCytochrome P450 3A4enzyme
DB09102DaclatasvirCytochrome P450 3A43enzyme
DB09102DaclatasvirCytochrome P450 3A7enzyme
DB09102DaclatasvirMultidrug resistance protein 1transporter
DB09102DaclatasvirSolute carrier organic anion transporter family member 1B1transporter
DB09102DaclatasvirSolute carrier organic anion transporter family member 1B3transporter
DB09102DaclatasvirATP-binding cassette sub-family G member 2transporter
DB09183DasabuvirNonstructural protein 5B (NS5B)target
DB09183DasabuvirCytochrome P450 2C8enzyme
DB09183DasabuvirCytochrome P450 3A4enzyme
DB09183DasabuvirCytochrome P450 2D6enzyme
DB09183DasabuvirUDP-glucuronosyltransferase 1A1enzyme
DB09183DasabuvirATP-binding cassette sub-family G member 2transporter
DB09183DasabuvirATP-binding cassette sub-family B member 5transporter
DB09183DasabuvirMultidrug resistance protein 1transporter
DB09296OmbitasvirNonstructural protein 5Atarget
DB09296OmbitasvirCytochrome P450 2C8enzyme
DB09296OmbitasvirMultidrug resistance protein 1transporter
DB09296OmbitasvirUDP-glucuronosyltransferase 1A1transporter
DB09296OmbitasvirATP-binding cassette sub-family G member 2transporter
DB09297ParitaprevirNS3/4A proteintarget
DB09297ParitaprevirCytochrome P450 3A4enzyme
DB09297ParitaprevirCytochrome P450 3A5enzyme
DB09297ParitaprevirATP-binding cassette sub-family G member 2transporter
DB09297ParitaprevirMultidrug resistance protein 1transporter
DB09297ParitaprevirSolute carrier organic anion transporter family member 1B1transporter
DB09297ParitaprevirSolute carrier organic anion transporter family member 1B3transporter
DB11574ElbasvirNonstructural Protein 5A (NS5A)target
DB11574ElbasvirMultidrug resistance protein 1transporter
DB11574ElbasvirCytochrome P450 3A4enzyme
DB11574ElbasvirCytochrome P450 3A5enzyme
DB11574ElbasvirCytochrome P450 3A7enzyme
DB11574ElbasvirCytochrome P450 3A43enzyme
DB11575GrazoprevirMultidrug resistance protein 1transporter
DB11575GrazoprevirSolute carrier organic anion transporter family member 1B1transporter
DB11575GrazoprevirSolute carrier organic anion transporter family member 1B3transporter
DB11575GrazoprevirCytochrome P450 3A4enzyme
DB11575GrazoprevirNS3/4A proteintarget
DB11575GrazoprevirSerum albumincarrier
DB11575GrazoprevirAlpha-1-acid glycoprotein 1carrier
DB11586AsunaprevirHepatitis C virus NS3 protease/helicasetarget
DB11586AsunaprevirMultidrug resistance protein 1carrier
DB11586AsunaprevirSolute carrier organic anion transporter family member 1B1carrier
DB11586AsunaprevirSolute carrier organic anion transporter family member 2B1carrier
DB11586AsunaprevirCYP3Aenzyme
DB11586AsunaprevirCytochrome P450 3A4enzyme
DB11586AsunaprevirCytochrome P450 3A5enzyme
DB11586AsunaprevirCytochrome P450 2A6enzyme
DB11586AsunaprevirCytochrome P450 2B6enzyme
DB11586AsunaprevirCytochrome P450 2C9enzyme
DB11586AsunaprevirCytochrome P450 2C19enzyme
DB11586AsunaprevirCytochrome P450 2D6enzyme
DB11586AsunaprevirSolute carrier organic anion transporter family member 1B1transporter
DB11586AsunaprevirSolute carrier organic anion transporter family member 1B3transporter
DB11586AsunaprevirSolute carrier organic anion transporter family member 2B1transporter
DB11613VelpatasvirCytochrome P450 2B6enzyme
DB11613VelpatasvirCytochrome P450 2C8enzyme
DB11613VelpatasvirCytochrome P450 3A4enzyme
DB11613VelpatasvirNonstructural Protein 5A (NS5A)target
DB11613VelpatasvirMultidrug resistance protein 1transporter
DB11613VelpatasvirATP-binding cassette sub-family G member 2transporter
DB11613VelpatasvirSolute carrier organic anion transporter family member 1B1transporter
DB11613VelpatasvirSolute carrier organic anion transporter family member 1B3transporter
DB11613VelpatasvirSolute carrier organic anion transporter family member 2B1transporter
DB12026VoxilaprevirCytochrome P450 3A4enzyme
DB12026VoxilaprevirCytochrome P450 1A2enzyme
DB12026VoxilaprevirCytochrome P450 2C8enzyme
DB12026VoxilaprevirNS3/4A proteintarget
DB12026VoxilaprevirMultidrug resistance protein 1transporter
DB12026VoxilaprevirATP-binding cassette sub-family G member 2transporter
DB12026VoxilaprevirSolute carrier organic anion transporter family member 1B1transporter
DB12026VoxilaprevirSolute carrier organic anion transporter family member 1B3transporter
DB13878PibrentasvirNonstructural Protein 5A (NS5A)target
DB13878PibrentasvirCYP3Aenzyme
DB13878PibrentasvirUDP-glucuronosyltransferase 1-1enzyme
DB13878PibrentasvirMultidrug resistance protein 1transporter
DB13878PibrentasvirATP-binding cassette sub-family G member 2transporter
DB13878PibrentasvirSolute carrier organic anion transporter family member 1B1transporter
DB13878PibrentasvirSolute carrier organic anion transporter family member 1B3transporter
DB13879GlecaprevirCYP3Aenzyme
DB13879GlecaprevirUDP-glucuronosyltransferase 1-1enzyme
DB13879GlecaprevirMultidrug resistance protein 1transporter
DB13879GlecaprevirATP-binding cassette sub-family G member 2transporter
DB13879GlecaprevirSolute carrier organic anion transporter family member 1B1transporter
DB13879GlecaprevirSolute carrier organic anion transporter family member 1B3transporter
DB13879GlecaprevirNS3 proteasetarget